BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
CLSA initiates Biocon with underperform
Upsides from Mylan partnership is likely to come only beyond 2017. Company is currently in a consolidation phase. Capacity constraints are likely to impact growth.